Chardan Capital Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $55
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $55.
September 18, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has initiated coverage on CervoMed with a Buy rating and a price target of $55, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a high price target suggests that Chardan Capital sees significant upside potential in CervoMed's stock. This is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100